Mediterranean Journal of Hematology and Infectious Diseases

Original Article

**Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles**

Mohamed A Yassin¹, Ashraf T Soliman², Vincenzo De Sanctis³, Radwa M Hussein⁴, Randa Al-Okka⁵, Nancy Kassem⁶, Rula Ghasoub⁴, Ahmed Basha⁴, Abdulqadir J Nashwan⁴ and Ahmad M. Adel⁴.

¹ Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, Qatar.
² Departments of Pediatrics, University of Alexandria, Alexandria, Egypt.
³ Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy.
⁴ Pharmacists, Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar.
⁵ Nurse Research Scientist, Cancer Clinical Trials Unit, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar.

**Competing interests:** The authors have declared that no competing interests exist.

**Abstract.** *Introduction:* Due to the chronic nature of chelation therapy and the adverse consequences of iron overload, patient adherence to therapy is an important issue. Jadenu ® is a new oral formulation of deferasirox (Exjade ®) tablets for oral suspension. While Exjade® is a dispersible tablet that must be mixed in liquid and taken on an empty stomach, Jadenu ® can be taken in a single step, with or without a light meal, simplifying administration for the treatment of patients with chronic iron overload. This may significantly improve the compliance to treatment of patients with β-thalassemia major (BMT). The aim of this study was to evaluate the drug tolerability and the effects of chelation therapy on serum ferritin concentration, liver iron concentration (LIC) and biochemical profiles in patients with BMT and iron overload.

*Patients and Methods:* Twelve selected adult patients BMT (mean age: 29 years; range:15-34 years) were enrolled in the study. All patients were on monthly regular red cell transfusion therapy to keep their pre-transfusional hemoglobin (Hb) level not less than 9 g/dL. They were on Exjade® therapy (30 mg/kg per day) for two years or more before starting Jadenu® therapy (14-28 mg/kg/day). The reason for shifting from Deferasirox® to Jadenu® therapy was lack of tolerability, as described by patients, such as nausea, vomiting, diarrhea, stomach pain. Most of them also reported that Deferasirox® was not palatable. Lab investigations included monthly urine analysis and measurement of their serum concentrations of creatinine, fasting blood glucose (FBG), serum ferritin, alkaline phosphatase (ALP), alanine transferase (ALT), aspartate transferase (AST) and albumin concentrations. LIC was measured using FerriScan ®. Thyroid function, vitamin D and serum parathormone, before and one year after starting Jadenu® therapy, were also assessed.

*Results:* Apart from some minor gastrointestinal complaints reported in 3 BMT patients that did not require discontinuation of therapy, other side effects were not registered during the treatment. Subjectively, patients reported an improvement in the palatability of Jadenu® compared to Exjade® therapy in 8 out of 12 BMT patients. A non-significant decrease in LIC measured by FerriScan® and serum ferritin levels was observed after one year of treatment with Jadenu®. A significant positive correlation was found between serum ferritin level and LIC measured by the FerriScan® method. LIC and serum ferritin level correlated significantly with ALT level (r = 0.31 and 0.45 respectively, p < 0.05). No significant correlation was detected between LIC and other biochemical or hormonal parameters.
Conclusions: Our study shows that short-term treatment with Jadenu® is safe but is associated with a non-significant decrease in LIC and serum ferritin levels. Therefore, there is an urgent need for adequately-powered and high-quality trials to assess the clinical efficacy and the long-term outcomes of new deferasirox formulation.

Keywords: Thalassemia major, Chelation therapy, Deferasirox, Liver iron concentration, Serum ferritin, Patient's satisfaction, Adverse events.

Citation: Yassin M.A., Soliman A.T., De Sanctis V., Hussein R.M., Al-Okra K., Kassem N., Ghasoub R., Basha A., Nashwan A.J., Adel A.M. Jadenu® substituting Exjade® in iron overloaded β-thalassemia major (BTM) patients: a preliminary report of the effects on the tolerability, serum ferritin level, liver iron concentration and biochemical profiles. Mediterr J Hematol Infect Dis 2018, 10(1): e2018064, DOI: http://dx.doi.org/10.4084/MJHID.2018.064

Published: November 1, 2018 Received: August 8, 2018 Accepted: October 10, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Mohamed A Yassin, MD. Consultant Hematologist, Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha (Qatar). E-mail: Yassinmoha@gmail.com

Introduction. In patients with β-thalassemia major (BTM), iron overload is the joint outcome of multiple blood transfusions and an inappropriately increased iron absorption. In BTM patients, the rate of transfusional and gastrointestinal (GI) tract iron accumulation is generally 0.3-0.6 mg/kg per day. Increased GI tract iron absorption can result from severe anemia and ineffective erythropoiesis (IE), which down-regulate the synthesis of hepcidin, a protein that controls iron absorption from the GI tract and the release of recycled iron from macrophages. Without correction, iron overload can lead to end-organ damage, resulting in cardiac, hepatic, and endocrine dysfunction/failure.

Iron chelation has been proven to decrease organ dysfunction and to improve survival in certain transfusion-dependent anemias, such as β-thalassemia. To date, there are 3 major classes of iron chelators: hexadentate (deferoxamine [DFO], Desferal®, Novartis Pharma AG, Basel, Switzerland), in which 1 atom of iron is bound to 1 DFO molecule; bidentate (deferriprone, [DFP] Ferriprox®, Apotex Inc., Toronto, ON, Canada), in which 1 atom of iron is bound to 3 DFP molecules; and tridentate (deferasirox [DFX], Exjade® and Jadenu®, Novartis Pharma AG, Basel, Switzerland), in which 1 atom of iron is bound to 2 DFX molecules. The intensive demands and uncomfortable side effects of therapy can have a negative impact on daily activities and well-being, which may affect adherence to treatment.

Exjade® is a once-daily, oral iron chelator that was developed out of a need for a long-acting, conveniently-administered chelator for patients with transfusional hemosiderosis. The approved mode of administration requires taking Exjade® on an empty stomach with water, apple juice or orange juice to limit variation in bioavailability. Any residual medication must be resuspended in a small volume of liquid and taken. This procedure leads to a lengthy mixing process and the theoretical risk of patients not completely taking the intended dose. Additionally, one third of patients find Exjade® as a tablet for oral suspension unpalatable. Additionally, approximately one-quarter of patients experience mild to moderate GI symptoms, which may pose additional challenges, particularly in the younger and older age ranges.

The new tablet DFX formulation (Jadenu®) was developed in an attempt to overcome these tolerability issues and is the only once-daily oral iron chelator that can be swallowed with a light meal, without the need to disperse into a suspension prior to consumption. It was approved by the FDA on March 31, 2015. The recommended initial dose of Jadenu® for patients 2 years of age and older, with estimated glomerular filtration rate (eGFR) greater than 60 mL/min/1.73 m², is 14 mg/kg/bdy weight given orally, once daily, and titrated up by 3.5–7 mg/kg/day. In patients not adequately controlled with doses of 21 mg per kg/day (e.g., serum ferritin levels persistently above 2,500 µg/L and not showing a decreasing trend over time), doses of up to 28 mg per kg may be considered. Doses above 28 mg per kg are not recommended.

When converting a patient from Exjade® to Jadenu®, the dosage should be decreased by 30% since the new formulation is more bioavailable than the original Exjade® formulation.
Up to now, the new DFX formulation has been evaluated in pharmacokinetic studies in healthy volunteers in an open-label, phase II ECLIPSE study, over 24 weeks in chelation-naïve or pre-treated patients (aged >10 years) with transfusion-dependent thalassemia or myelodysplastic syndromes. Patients reported greater adherence and satisfaction, better palatability and fewer concerns with Deferasirox® than Jadenu®. Treatment compliance by pill count was higher with latter compound: 92.9% vs. 85.3%. Our study aimed to evaluate the patient satisfaction, the adverse events (AEs) and the effects of Jadenu® treatment on serum ferritin concentration, liver iron concentrations (LIC) measured by FerriScan® and biochemical profiles in BTM patients with iron overload.

**Patients and Methods.** A pre-selected group of twelve adult patients with BTM that couldn't tolerate Exjade® therapy were enrolled in our study. The reason for shifting from Deferasirox® to Jadenu® therapy was the lack of tolerability as described by patients, such as nausea, vomiting, diarrhea, stomach pain. Most of them also reported that Deferasirox® was not palatable.

The mean age of patients was 29 years (range:15-34 years). Six patients were males, and 2 out of 12 patients were splenectomized. All patients were on regular packed red cell transfusion therapy to keep their pre-transfusional Hb level not less than 9 g/dL. They were on Exjade® therapy (30 mg/kg per day) for two years or more before substitution to Jadenu® therapy. All patients started with a dose of 14 mg/kg/day then escalated to a maximum dose of 28 mg/kg/day.

The efficacy and tolerability of iron chelation therapy were regularly analyzed and recorded before the blood transfusions. Doctors, taking care of BTM patients asked, during the study, the patient's satisfaction, palatability of medicine, and the presence of side effects. Safety was evaluated by monitoring and assessing AEs, changes in laboratory parameters, and clinical observations from the start of study treatment to 30 days after the last intake of study drug.

Lab investigations included monthly urine analysis and measurement of their serum concentrations of creatinine, fasting blood glucose (FBG), serum ferritin, alkaline phosphatase (ALP), alanine transferase (ALT), aspartate transferase (AST) and albumin concentrations. LIC was measured using Ferriscan®. LIC values were expressed as mg/g /dry weight and classified into: normal (LIC <3 mg/g /dry weight); mild (LIC > 3 and < 7 mg/g /dry weight), moderate (LIC > 7 and < 14 mg/g /dry weight) and severe overload (LIC ≥ 15 mg Fe/g dry weight). In addition, thyroid function [free T4 (FT4), thyrotropin (TSH)], 25 OH vitamin D and serum parathormone (PTH) levels were measured before and one year after starting Jadenu® therapy. All patients were on vitamin D (800 U/day) and folic acid (5 mg/day).

The paired t-Student test was used to compare lab results before versus after Jadenu® treatment. Linear regression was used to investigate a possible relation between variables (LIC vs. serum ferritin level, LIC vs. other biochemical or hormonal parameters). A p value < 0.05 was considered as significant.

Ethical approval for the study was obtained by the Ethical Committee of Hamad General Hospital. All procedures were carried out with the adequate understanding and consent of patients.

**Results.** Subjectively, 8 out of 12 BMT patients reported an improvement in the palatability of Jadenu® compared to Exjade® therapy. Apart from some minor gastrointestinal complaints, reported in 3 BMT patients, that did not require discontinuation of therapy, other side effects were not registered during the treatment.

A non-significant statistical decrease in serum ferritin concentration and LIC values was observed after one year of Jadenu® treatment. No significant variations were observed for urine analysis, serum creatinine, albumin, ALP, ALT, AST, FBG, thyroid function, vitamin D and PTH levels (Tables 1 and 2).

A significant positive correlation was found between serum ferritin level and LIC, measured by the FerriScan® method (r= 0.61, p: 0.03). LIC and serum ferritin level were also correlated significantly to ALT level (r = 0.31 and 0.45 respectively, p < 0.05). No significant correlation was detected between LIC and other biochemical or hormonal parameters.

**Discussion.** There are currently four different types of iron chelator readily available for patients with thalassemia: deferoxamine/DFO (branded as Desferal), deferiprone/DFP (branded as Ferriprox®), deferasirox/DFX (branded as Exjade® and Jadenu®). Each of the four chelators offers...
Table 1. Biochemical data before versus after Jadenu® treatment in patients with β-thalassemia major.

|                | Serum creatinine | Albumin | ALP     | ALT     | AST     | FBG     |
|----------------|------------------|---------|---------|---------|---------|---------|
| **On Exjade ®**| Mean             | 71.25   | 45.75   | 136.00  | 41.08   | 35.75   | 5.75    |
| **n = 12**     | SD               | 4.88    | 4.69    | 106.04  | 33.65   | 22.84   | 1.10    |
| **On Jadenu ®**| Mean             | 72.67   | 45.00   | 113.50  | 25.50   | 33.08   | 5.73    |
| **n = 12**     | SD               | 3.75    | 2.74    | 52.44   | 8.87    | 16.86   | 1.15    |
|                | P value           | 0.12    | 0.28    | 0.16    | 0.08    | 0.36    | 0.48    |

Legend: ALP = alkaline phosphatase (U/L); ALT = alanine transferase (U/L); AST = aspartate transferase (U/L); FBG = fasting blood glucose (mmol/L). The reference ranges for albumin and serum creatinine are as follows: 35-55 g/L; adult women: 0.6-1.1 mg/dL (53-97 μmol/L) - adult men: 0.7-1.3 mg/dL (80-115 μmol/L).

Table 2. Liver iron content, serum ferritin and hormonal parameters in patients with β-thalassemia major before and after Jadenu ® treatment.

|                | LIC (mg/g dry weight) | SF (ng/ml) | TSH (mIU/L) | FT4 (pmol/L) | PTH (ng/ml) | Vit.D (ng/ml) |
|----------------|-----------------------|------------|-------------|--------------|-------------|---------------|
| **On Exjade ®**| Mean                  | 29.47      | 2716.92     | 2.51         | 12.34       | 25.75         | 14.22        |
| **n = 12**     | SD                    | 16.01      | 2101.93     | 1.36         | 1.21        | 3.49          | 3.12         |
| **On Jadenu ®**| Mean                  | 26.66      | 2552.80     | 2.44         | 12.41       | 26.20         | 19.78        |
| **n = 12**     | SD                    | 13.48      | 1512.92     | 0.87         | 1.00        | 4.21          | 9.06         |
|                | P value               | 0.31       | 0.36        | 0.41         | 0.40        | 0.13          | 0.09         |

Legend: LIC (mg/g dry weight) = Liver iron concentration; SF (ng/ml) = Serum ferritin; TSH (mIU/L) = thyrotropin; FT4 (pmol/L) = free T4; PTH (ng/ml) = serum parathormone; Vit. D (ng/ml) =25 OH vitamin D.

different benefits and challenges to the patients.

Usage of DFP or DFX, as oral chelator is more preferably due to its ease of use, with several studies presenting higher compliance rate in LeoGib1707 patients with oral chelator compared to DFO injection (s.c. or i.v.) chelator. People treated with all chelators must be kept under close medical supervision and treatment with DFO or DFX requires regular monitoring of neutrophil counts or renal function, respectively.

Patients taking DFX tablets for oral suspension (Exjade®) reported superior satisfaction scores compared to those reported by patients taking DFO, with satisfaction rates for DFX as high as 90%. However, palatability studies showed that more than third of patients disliked DFX (Exjade®) tablets for oral suspension, with self-reported adherence to the medication varying from 67% to 85%.

The most common side effect with DFX tablets is GI discomfort, with 10%–33% of patients experiencing abdominal pain, diarrhea, nausea, and/or vomiting.

However, most patients are able to tolerate these side effects, although 7% of patients cited GI side effects as a reason for stopping treatment. As DFX can cause renal toxicity and proteinuria, creatinine should be monitored twice prior to the initiation of therapy and monthly thereafter.

The new DFX formulation (Jadenu®) thanks to the simplification of its administration is hoped to improve patient satisfaction, and thereby adherence to treatment. Subjectively, 8 out of 12 BMT patients (66.6%) enrolled in our study reported an improvement in the palatability of Jadenu® compared to Exjade® therapy. Three out of 12 BTM patients (25%) reported nausea and abdominal discomfort on Jadenu® therapy, but none of these symptoms required discontinuation of treatment. During the study period, we did not register significant changes in serum creatinine concentrations, albumin levels, and urine analysis, as well as for glucose levels and thyroid function.

Lever iron overload and hepatic dysfunction are major side effects of chronic transfusion therapy. Measurement of LIC is the most reliable indicator of body iron load. Normal LIC values are up to 1.8 mg/g dry weight, with levels of up to 7 mg/g dry weight seen in some non-thalassemic populations without apparent adverse effects. Sustained high LIC (above 15-20 mg/g dry weight) have been linked to worsening prognosis and liver fibrosis progression. Adequate control of LIC is linked to the risk of hepatic damage as well as the risk of extrahepatic damage.

After one year of treatment with Jadenu®, a non-significant decrease in LIC and serum ferritin
levels was observed in our patients. The term non-
responder has been used to describe individuals
who fail to show a downward trend in iron balance
(changes in LIC) and extratherapeutic iron distribution
(myocardial T2*). Lack of a response of an
individual may result from inadequate dosing,
high transfusion requirement, poor treatment
adherence, or unfavorable pharmacology of the
chelation regime.21,22

In our patients, the dosage of oral iron chelation
therapy was appropriate, the blood consumption
was not increased, but the compliance to treatment
was not fully evaluated, and the pharmacokinetic
and pharmacodynamic profile of the new
deferasirox formulation were not performed. In
general, the new formulation has comparable
pharmacokinetic to the dispersible tablet
formulation. However, the new formulation is
more bioavailable than the original Exjade®,
and the peak serum concentrations (Cmax) is
approximately 30% higher.9,10

A significant correlation between LIC assessed
by FerriScan® and serum ferritin levels was
observed in the current study. Although the small
numbers preclude a generalization, this is in line
with the findings of Zamani et al.23 and Majd et
al.24 who reported that serum ferritin is a good
parameter to detect hepatic iron loading. Serum
ferritin remains an inexpensive and easily
available tool for assessment of iron overload and
can be used in areas where access to liver T2 MRI
assessment is unavailable or limited. However,
ferritin trends need to be interpreted with caution
before critical changes are made in the chelation
plan because trends in ferritin can be dramatically
different from changes in LIC as assessed by
MRI.25

Conclusions. Once the need for iron chelators is
established in patients with transfusional iron
overload, the ideal agent should be determined by
the practitioner and patient. DFX (Exjade®) is a
frequent choice due to ease of once-daily oral
administration, but adherence may be hampered
by palatability of the tablet for oral suspension.

Although some limitations are present in our
study: (a) it was performed only in a single centre,
and (b) the number of patients enrolled in the
study was small, our results confirm that short-
term treatment with Jadenu® is safe, has a better
palatability and fewer patients' concerns versus the
original formulation. However, it was associated
with a non-significant decrease in LIC and serum
ferritin levels. Therefore, there is an urgent need
for further research assessing the clinical efficacy
and the long-term outcomes of the new DFX
formulation.

References:

1. Pippard M. Iron chelation therapy in the treatment of iron overload. In: Bergeron R, Brittenham G, eds. The Development of Iron Chelators for Clinical Use. Boca Raton, FL: CRC Press; 1994:57–74.

2. Tanno T, Bhanu NV, Osona PA, Geh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Br J Haematol. 2007;13:1096–1101. https://doi.org/10.1038/nm1629

3. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-1995. https://doi.org/10.1056/NEJM199912233412460

4. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107:3436-3441. https://doi.org/10.1182/blood-2006-02-023594

5. Fortin PM, Fisher SA, Madwick KV, Travella M, Hopewell S, Doree C, Escourt LJ. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database Syst Rev. 2018 May 8:5.CD012349. https://doi.org/10.1002/14651858.CD012349.pub2

6. Waldmeier F, Bruin GI, Glanzel U, Hazell K, Sechaud R, Warrington S, Porter JB. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassaemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010;38:808–816. https://doi.org/10.1124/dmd.109.038033

7. Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60:1507–1512. https://doi.org/10.1002/pbc.24561

8. Chalmers AW, Shammo JM. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag. 2016 Feb 15;12:201-8. https://doi.org/10.2147/TRM.S82449

9. Novartis Pharmaceuticals Corporation. Highlights of prescribing information: Jadenu®. New Jersey, US: Novartis; 2015. [Accessed January 7, 2016]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/jadenu.pdf
10. Shah NR. Advances in iron chelation therapy: transitioning to a new oral formulation. Drugs Context. 2017 Jun 16;6:212502. https://doi.org/10.7573/djc.212502

11. Taher AT, Origa R, Perrotta S, Kourakli A, Rufuo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS. Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017;92:420-428. https://doi.org/10.1002/ajh.24668 PMid:28142202

12. Yassim MA, Soliman AT, De Sanctis V, Abdula MA, Riaz LM, Ghori FF, Yousaf A, Nashwan AJ, Abusamaan S, Moustafa A, Kohlha S, Soliman DS. Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD). Acta Biomed. 2018;89(2-S):33-40.

13. Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of Liver Iron with MRI. State of the Art and Remaining Challenges. J Magn Reson Imaging.2014;40:1093-1021. https://doi.org/10.1002/jmri.24584 PMid:24585403 PMCid:PMC4308740

14. Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450. https://doi.org/10.1002/14651858.CD004450.pub3

15. Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swardlow P, Coates TD. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol. 2014;89:391-394. https://doi.org/10.1002/ajh.23650 PMid:23637051

16. Porter JB, Bowden DK, Economou M, Troncy J, Ganser A, Habr D, Martin N, Gater A, Rofail D, Abetz-Webb L, Lau H, Cappellini MD. Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial. Anemia. 2012:2012:297641. https://doi.org/10.1155/2012/297641

17. Angelucci E., Urru S.A.M., Pilo F., Piperno A. Myelodysplastic syndromes and iron chelation therapy. Mediterr J Hematol Infect Dis 2018; 10. https://doi.org/10.4084/mjhid.2017.021

18. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferoxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632–4639. https://doi.org/10.1182/blood-2002-09-2754 PMid:12576333

19. Porter JB, Shah FT, Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am. 2010;24:1109-1130. https://doi.org/10.1016/j.hoc.2010.08.015 PMid:21075283

20. Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012;8:123-134. https://doi.org/10.1517/17425255.2012.640674 PMid:22176640

21. Zamani F, Razmjou S, Akhlaghpour S, Eslami SM, Azarekan A, Amir A. T2* magnetic resonance imaging of the liver in thalassemic patients in Iran. China Natl J New Gastroenterol. 2011;17:522 – 525.

22. Majd Z, Haghpanah S, Ajami GH, Matin S, Namazi H, Bardestani M, Karimi M. Serum Ferritin Levels Correlation With Heart and Liver MRI and LIC in Patients With Transfusion-Dependent Thalassemia Iran Red Crescent Med J. 2015 Apr 25;17(4):e24959. https://doi.org/10.5812/ircmj.17(4)2015.24959

23. Puliyel M, Sposto R, Berdoukas VA, Hofstra TC, Nord A, Carson S, Wood J, Coates TD. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol. 2014;89:391-394. https://doi.org/10.1002/jhj.23650 PMid:24347294